Canaccord analyst John Young lowered the firm’s price target on Merit Medical (MMSI) to $93 from $104 and keeps a Buy rating on the shares. The firm noted the company’s announement that CMS had notified the company that its application for Transitional Pass-Through, which would have provided incremental reimbursement for Wrapsody in the outpatient and ASC settings, would require further consideration from CMS prior to it making a final decision.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Systems: Strategic Adjustments and Growth Potential Justify Buy Rating
- Closing Bell Movers: Applied Materials down 4% after earnings and guidance
- Merit Medical Systems Begins WRAPSODY CIE Commercialization
- CMS notifies Merit that Wrapsody reimbursement requires further consideration
- Merit Medical releases 24-month efficacy results from AVF arm of WAVE trial